Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index; 65 of the 230 sources its claims cite were checked for support.

Signals Alongside Scans: A Genomics-Guided Framework for Liquid Biopsy in Bone and Soft-Tissue Sarcomas

Open access

Abstract

Background: Bone and soft-tissue sarcomas are rare, heterogeneous malignancies whose surveillance remains dominated by imaging despite substantial molecular diversity and variable patterns of relapse. Circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) offer minimally invasive approaches for monitoring tumor biology, but their performance in sarcoma depends strongly on subtype, disease burden, assay design, and biological shedding. Methods: This narrative review synthesizes evidence published from 2015 to 2026 on ctDNA and CTCs for baseline risk assessment, treatment-response monitoring, minimal residual disease (MRD) detection, molecular relapse, and integration with imaging-based surveillance in bone and soft-tissue sarcomas. Results: Current evidence supports a genomics-guided framework in which liquid-biopsy strategy is selected according to sarcoma subtype, molecular architecture, and clinical purpose. ctDNA is the most mature analyte, with best-supported evidence in osteosarcoma, where tumor-informed assays predict postoperative relapse, and in translocation-associated sarcomas, where breakpoint-guided assays enable highly specific longitudinal monitoring. Copy-number-based approaches are relevant for complex-karyotype tumors, while mutation-, methylation-, fragmentomic-, and RNA-based strategies may be useful in selected contexts. However, detection rates vary, false-negative results occur in low-shedding or low-volume disease, and clinical utility for changing treatment remains incompletely established. CTCs provide complementary cellular and prognostic information, particularly in osteosarcoma, but remain limited by platform heterogeneity and incomplete standardization. Conclusion: Liquid biopsy may refine risk stratification, support treatment-response assessment, clarify indeterminate imaging findings, and identify molecular relapse in selected sarcoma patients. At present, it should be interpreted as an adjunct to imaging and specialist multidisciplinary care rather than as a replacement for standard radiologic surveillance.

Overview

CoChat Summary

TL;DR

This narrative review argues that liquid biopsy in bone and soft-tissue sarcomas should be “genomics-guided,” meaning the assay should match the tumor’s molecular architecture and the clinical question rather than using one universal platform. ctDNA has the strongest near-term support, especially for baseline risk, treatment response, MRD, and molecular relapse in osteosarcoma and translocation-associated sarcomas, while CTCs are promising but less standardized.

Key findings

  • The literature search identified 1284 records; after removing 347 duplicates, 937 titles/abstracts were screened, 124 full texts were assessed, and 53 sources were included in the narrative synthesis.
  • In a Children’s Oncology Group cohort, ctDNA was detectable in more than half of newly diagnosed Ewing sarcoma and osteosarcoma cases, and detectable ctDNA was associated with inferior outcomes, particularly in localized Ewing sarcoma.
  • In the largest osteosarcoma MRD cohort described, tumor-informed MRD panels were generated in 71 of 83 patients; postoperative ctDNA predicted inferior event-free survival and preceded positive imaging in 5 patients, with a mean lead time of 92.6 days.
  • For osteosarcoma CTCs, one study detected CTCs in 30 of 32 patients before treatment (mean 14.06 ± 9.08), another in 28 of 30 patients (median 6 CTCs per 5 mL), and a third found CTCs in 43 of 50 patients with IMP3-positive CTC count showing AUC 0.873, 87.5% sensitivity, and 82.4% specificity for identifying metastasis.

Methods

  • Narrative review of circulating biomarkers in bone and soft-tissue sarcomas, focusing on ctDNA, cfDNA, cfRNA, CTCs, and other circulating biomarkers for risk assessment, response monitoring, MRD, relapse surveillance, and imaging integration.
  • Structured searches were conducted in PubMed and Scopus for studies published between January 2015 and 1 April 2026, with additional targeted searches and manual reference screening.
  • Evidence was synthesized qualitatively; the paper states that it was not a formal systematic review or meta-analysis, and no quantitative meta-analysis was performed.

Limitations

  • The paper states that most available studies are small, single-center, heterogeneous, and often retrospective, with variable sampling schedules and limited multicenter validation.
  • It notes substantial assay heterogeneity across studies, including differences in plasma processing, cfDNA input, sequencing depth, error suppression, positivity thresholds, and handling of clonal hematopoiesis.
  • It also emphasizes that low-shedding disease limits detection, so “ctDNA not detected” may reflect biology or technical sensitivity rather than true absence of disease; this is especially important in postoperative MRD and molecular relapse settings.
  • Evident from the text: because this is a narrative review, its conclusions are based on selective synthesis rather than a fully systematic, quantitatively pooled evidence base.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/cells15141271

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Study-selection workflow for the narrative review. The diagram summarizes database identification, duplicate removal, title and abstract screening, full-text assessment, and final source inclusion. Because this article is a narrative review rather than a formal systematic review or meta-analysis, the workflow is presented to improve methodological transparency rather than to indicate full PRISMA-based systematic-review methodology. * Identified from PubMed and Scopus. ** Records were excluded at title/abstract screening primarily because they were (1) not sarcoma-specific or not directly relevant to bone or soft-tissue sarcoma, or (2) not focused on liquid biopsy, circulating biomarkers, MRD, treatment-response monitoring, surveillance, or clinical implementation.
Figure 1 Study-selection workflow for the narrative review. The diagram summarizes database identification, duplicate removal, title and abstract screening, full-text assessment, and final source inclusion. Because this article is a narrative review rather than a formal systematic review or meta-analysis, the workflow is presented to improve methodological transparency rather than to indicate full PRISMA-based systematic-review methodology. * Identified from PubMed and Scopus. ** Records were excluded at title/abstract screening primarily because they were (1) not sarcoma-specific or not directly relevant to bone or soft-tissue sarcoma, or (2) not focused on liquid biopsy, circulating biomarkers, MRD, treatment-response monitoring, surveillance, or clinical implementation.CC BY · PubMed Central
Figure 2 Genomics-guided liquid-biopsy framework in sarcoma. Standard tissue diagnosis, histopathology, molecular pathology, and imaging remain foundational. Liquid-biopsy assay selection is then guided by sarcoma subtype, molecular architecture, and the clinical question. Translocation-associated sarcomas are suited to fusion- or breakpoint-guided ctDNA assays, whereas complex-karyotype sarcomas may require tumor-informed, personalized, methylation-based, fragmentomic, or copy-number-based approaches. Liquid biopsy may support baseline risk assessment, treatment-response monitoring, postoperative MRD detection, and molecular relapse surveillance but should complement rather than replace imaging. Abbreviations: ctDNA, circulating tumor DNA; CTCs, circulating tumor cells; ddPCR, digital droplet PCR; NGS, next-generation sequencing; MRD, minimal residual disease; LPS, liposarcoma; UPS, undifferentiated pleomorphic sarcoma; LMS, leiomyosarcoma; DDLPS, dedifferentiated liposarcoma.
Figure 2 Genomics-guided liquid-biopsy framework in sarcoma. Standard tissue diagnosis, histopathology, molecular pathology, and imaging remain foundational. Liquid-biopsy assay selection is then guided by sarcoma subtype, molecular architecture, and the clinical question. Translocation-associated sarcomas are suited to fusion- or breakpoint-guided ctDNA assays, whereas complex-karyotype sarcomas may require tumor-informed, personalized, methylation-based, fragmentomic, or copy-number-based approaches. Liquid biopsy may support baseline risk assessment, treatment-response monitoring, postoperative MRD detection, and molecular relapse surveillance but should complement rather than replace imaging. Abbreviations: ctDNA, circulating tumor DNA; CTCs, circulating tumor cells; ddPCR, digital droplet PCR; NGS, next-generation sequencing; MRD, minimal residual disease; LPS, liposarcoma; UPS, undifferentiated pleomorphic sarcoma; LMS, leiomyosarcoma; DDLPS, dedifferentiated liposarcoma.CC BY · PubMed Central

Verification

Claims the paper makes

23 Valid · 4 Not valid · 59 Not checked · 60 Own results and interpretations

77 more claims · 16 with their cited sources checked

Create a free account to see all 146 claims and to verify the 165 references still open.

See all claims — free account
  • Probably not a substantial claim. 18
  • It may state two separate claims as one. 51

Create a free account to see these claims.

Citations

Cites

Show all 51 references

Research works printed but not linked: 4

  1. Vilanova, 2025, Soft tissue tumor imaging in adults: European Society of Musculoskeletal Radiology–Guidelines 2024: Imaging immediately after neoadjuvant therapy in soft tissue sarcoma, soft tissue tumor surveillance, and the role of interventional radiology, Eur. Radiol., 35, 3324
  2. Kara, 2022, Osteosarcoma: Novel prognostic biomarkers using circulating and cell-free tumour DNA, Eur. J. Cancer, 168, 1
  3. Young, 2024, CIRCUS: CIRCUlating tumour cells in soft tissue Sarcoma—A short report, Cancer Drug Resist., 7, 51
  4. Nawan, 2022, Detection and Quantification of Circulating Tumor Cells in Salvaged Blood in Surgical Osteosarcoma Patients: A Pilot Study from a Tertiary Medical Center, Biomed. Environ. Sci., 35, 366

Cited by

Still being checked.

Metadata

Authors
Alabid, I., Yousef, A. J., Patni, M. M., Aloti, R. A., Qassim, Z. A.-A. M., Alothman-Agha, A. A., Hamdy, H. A., Noury, F. M., & Abdelfattah, M. T.
Affiliations
  • Ras al-Khaimah Medical and Health Sciences University (AE)
  • Consultant Orthopaedic and Joint Replacement Surgeon, Department of Spine and Orthopaedic Surgery, RAK Hospital, Ras Al Khaimah 11393, United Arab Emirates
Corresponding author
  • Alabid, Ibrahim
  • Patni, Mohamedanas Mohamedfaruk
Venue
Cells
Publisher
MDPI AG
Published
2026-07-15
Volume
15
Issue
14
Pages
1271
ISSN
2073-4409 (ISSN-L)
OpenAlex
W7168401412
Cited by
0
References
51
FWCI
0.00
Type
journal article
Language
en
Open access
Locations
  • Cells (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords
liquid biopsy, bone sarcoma, soft tissue sarcoma, osteosarcoma, circulating tumor DNA, circulating tumor cells, minimal residual disease, molecular relapse, treatment response monitoring, risk stratification
MeSH terms
Liquid Biopsy, Circulating Tumor DNA, Bone Neoplasms, Humans, Neoplastic Cells, Circulating, Sarcoma, Biomarkers, Tumor, Genomics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Signals Alongside Scans: A Genomics-Guided Framework for Liquid Biopsy in Bone and Soft-Tissue Sarcomas. https://app.cochat.ai/papers/10.3390/cells15141271
The paper
Alabid, I., Yousef, A. J., Patni, M. M., Aloti, R. A., Qassim, Z. A.-A. M., Alothman-Agha, A. A., Hamdy, H. A., Noury, F. M., & Abdelfattah, M. T. (2026). Signals Alongside Scans: A Genomics-Guided Framework for Liquid Biopsy in Bone and Soft-Tissue Sarcomas. Cells. https://doi.org/10.3390/cells15141271

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.